Mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes. Learn more
  • Edit

Recent News about Immunai

More about Immunaiinfo icon

Immunai is a startup that operates in the healthcare and biotechnology sector, specifically focusing on the development of immunomodulatory drugs. The company uses a combination of immunomics and machine learning to create these drugs, which are designed to reprogram the immune system for better disease detection, diagnosis, and treatment. The company's team is composed of a diverse group of professionals, including immunologists, engineers, drug developers, computer scientists, and entrepreneurs.

Immunai's business model revolves around the research, development, and commercialization of these novel therapeutics. They aim to find and validate targets for their drugs, which are then developed and sold to healthcare providers. The company's clients are primarily in the healthcare sector, including hospitals, clinics, and other medical facilities.

The company was co-founded by Noam Solomon, who has a double Ph.D. in Math and Computer Science and has a background in both industry and academia. Other key team members include Tali Raveh-Sadka, the VP of Computational Biology, and Sen Zhang, the Vice President of Product.

In summary, Immunai is a biotech startup that uses advanced technology to develop innovative drugs that can reprogram the immune system, with the goal of improving disease detection, diagnosis, and treatment. The company operates in the healthcare sector and generates revenue through the sale of its therapeutics to medical facilities.

Keywords: Immunai, biotechnology, healthcare, immunomodulatory drugs, machine learning, immunomics, disease detection, disease diagnosis, disease treatment, therapeutics.

Tech stack

Tech stackLearn more about the technologies and tools that this company uses.

Investments by Immunai

ACQUISITION by Immunai Jul 2021
Dropprint Genomics
ACQUISITION by Immunai Mar 2021